Vesnarinone

Vesnarinone is a cardiotonic agent, mixed phosphodiesterase 3 inhibitor and ion-channel modifier that has modest, dose-dependent, positive inotropic activity, but minimal negative chronotropic activity. Vesnarinone improves ventricular performance most in patients with the worst degree of heart failure.

Product information

CAS Number: 81840-15-5

Molecular Weight: 395.45

Formula: C22H25N3O4

Synonym:

RG-0210

OPC-8212

Piteranometozine

Vesnarinone

Arkin-Z

RG 0210

RG0210

OPC 8212

OPC8212

Arkin

Chemical Name: 6-[4-(3,4-dimethoxybenzoyl)piperazin-1-yl]-3,4-dihydro-1H-quinolin-2-one

Smiles: COC1=CC=C(C=C1OC)C(=O)N1CCN(CC1)C1=CC2CCC(=O)NC=2C=C1

InChiKey: ZVNYJIZDIRKMBF-UHFFFAOYSA-N

InChi: InChI=1S/C22H25N3O4/c1-28-19-7-3-16(14-20(19)29-2)22(27)25-11-9-24(10-12-25)17-5-6-18-15(13-17)4-8-21(26)23-18/h3,5-7,13-14H,4,8-12H2,1-2H3,(H,23,26)

Technical Data

Appearance: Solid Power.

Purity: ≥98% (or refer to the Certificate of Analysis)

Solubility: Soluble in DMSO, not in water

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis

Storage Condition: Dry, dark and -20 ^oC for 1 year or refer to the Certificate of Analysis.

Shelf Life: ≥12 months if stored properly.

Stock Solution Storage: 0 - 4 ^oC for 1 month or refer to the Certificate of Analysis.

Drug Formulation: To be determined.

HS Tariff Code: 382200

References:

1. Hotta K, Nashimoto A, Yasumura E, Suzuki M, Azuma M, Iizumi Y, Shima D, Nabeshima R, Hiramoto M, Okada A, Sakata-Sogawa K, Tokunaga M, Ito T, Ando H, Sakamoto S, Kabe Y, Aizawa S, Imai T, Yamaguchi Y, Watanabe H, Handa H. Vesnarinone suppresses TNFα mRNA expression by inhibiting valosin-containing protein. Mol Pharmacol. 2013 May;83(5):930-8. doi: 10.1124/mol.112.081935. Epub 2013 Feb 7. PubMed PMID: 23393163.
2. Uchida D, Onoue T, Begum NM, Kuribayashi N, Tomizuka Y, Tamatani T, Nagai H, Miyamoto Y. Vesnarinone downregulates CXCR4 expression via upregulation of Krüppel-like factor 2 in oral cancer cells. Mol Cancer. 2009 Aug 12;8:62. doi: 10.1186/1476-4598-8-62. PubMed PMID: 19671192; PubMed Central PMCID: PMC2738650.
3. Harada K, Supriatno, Yoshida H, Sato M. Vesnarinone inhibits angiogenesis and tumorigenicity of human oral squamous cell carcinoma cells by suppressing the expression of vascular endothelial growth factor and interleukin-8. Int J Oncol. 2005 Dec;27(6):1489-97. PubMed PMID: 16273203.

Products are for research use only. Not for human use.